South Korea’s Ministry of Food and Drug Safety (MFDS) approved Curocell’s Limcato (anbalcabtagene-autoleucel; anbal-cel), marking the first MFDS-cleared homegrown CAR T therapy. The treatment is authorized for patients with advanced diffuse large B-cell lymphoma. The decision spotlights continued growth of domestic cell-therapy manufacturing and regulatory capability in Asia, where CAR T access has historically depended on imported products. It also signals how national health agencies are managing the unique quality and clinical oversight requirements of autologous immunotherapies. Clinicians will likely watch early post-approval adoption, including real-world outcomes and how MFDS approval data translate into operational capacity for manufacturing and patient scheduling.